Evidence map›Paper›PMID 38911272›Full record

ArticleTransplantation direct2024

Sex-based Disparities in Liver Transplantation for Hepatocellular Carcinoma and the Impact of the Growing Burden of NASH.

Jia Hong Koh, Douglas Chee, Cheng Han Ng, Karn Wijarnpreecha, Mark Muthiah, Darren Jun Hao Tan, Wen Hui Lim, Rebecca Wenling Zeng, Benjamin Koh, Eunice Tan Xiang Xuan and 10 more

Abstract read
In one paragraph

Article in Transplantation direct, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. The obese transplant organ recipient: experimental and clinical evidence for tailored immunosuppression.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
  3. Sex and gender disparities in hepatocellular carcinoma: insights into risk, diagnosis, and therapeutic outcomes.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jia Hong KohDivision of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
Douglas CheeDivision of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
Cheng Han NgDivision of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
Karn WijarnpreechaDivision of Gastroenterology and Hepatology, University of Arizona College of Medicine, Phoenix, AZ.
Mark MuthiahDivision of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
Darren Jun Hao TanMBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Wen Hui LimMBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Rebecca Wenling ZengMBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Benjamin KohMBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Eunice Tan Xiang XuanDivision of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
Glenn BonneyDepartment of Surgery, National University Hospital, Singapore, Singapore.
Shridhar IyerDepartment of Surgery, National University Hospital, Singapore, Singapore.
Dan Yock YoungDivision of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
Toru NakamuraDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume City, Fukuoka, Japan.
Hirokazu TakahashiLiver Center, Saga University Hospital, Saga, Japan.
Mazen NoureddinHouston Liver Institute, Houston, TX.
Mohammad Shadab SiddiquiDivision of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA.
Tracey G SimonDivision of Gastroenterology, Massachusetts General Hospital, Boston, MA.
Rohit LoombaDivision of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, CA.
Daniel Q HuangNational University Centre for Organ Transplantation, National University Health System, Singapore.

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Yeast Genetics and Stress Response Genes-BiomedicalP42ES010337 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUKEY, ROBERT H · 2000 to 2022
$69.8M
Pediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4M
Tissue-specific roles of FXR in CVD and NASHP01HL147835 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2024
$12.2M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LARS ECKMANN, Bernd G. Schnabl · 2019 to 2026
$10.8M
HIV MASLD Clinical Research Network (HCRN)R01DK121378 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI NAGA P CHALASANI, ROHIT LOOMBA · 2020 to 2026
$8.7M
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLDR01DK106419 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT, SIRLIN, CLAUDE B · 2015 to 2019
$3.4M
San Diego Cirrhosis Clinical Research NetworkU01DK130190 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2021 to 2026
$2.3M
Non-invasive screening of diabetics for advanced fibrosis due to NAFLDR01DK124318 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2022
$1.7M
NCATS NIH HHS UL1 TR001442NHLBI NIH HHS P01 HL147835NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK106419NIDDK NIH HHS R01 DK121378NIDDK NIH HHS R01 DK124318NIDDK NIH HHS U01 DK061734NIDDK NIH HHS U01 DK130190NIEHS NIH HHS P42 ES010337
6 · The paper itself

Abstract

Background: The cause of liver disease is changing, but its impact on liver transplantation (LT) for hepatocellular carcinoma (HCC) in women and men is unclear. We performed a nationwide study to assess the prevalence and posttransplant survival outcomes of the various causes of liver disease in women and men with HCC. Methods: Data were obtained from the United Network for Organ Sharing database from 2000 to 2022. Data related to the listing, transplant, waitlist mortality, and posttransplant mortality for HCC were extracted. The proportion of HCC related to the various causes of liver disease among LT candidates and recipients and posttransplant survival were compared between women and men. Results: A total of 51 721 individuals (39 465 men, 12 256 women) with HCC were included. From 2000 to 2022, nonalcoholic steatohepatitis (NASH) was the fastest-growing cause of liver disease among female LT candidates with HCC ( Conclusions: Women have a significantly longer waitlist duration compared with men. NASH is now the leading cause of liver disease among both female and male LT candidates and recipients with HCC.

Identifiers

PMID38911272
PMCPMC11191941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.